The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1b study of unesbulin (PTC596) plus dacarbazine for the treatment of patients with locally recurrent, unresectable, or metastatic relapsed/refractory leiomyosarcoma.
 
Brian Andrew Van Tine
Leadership - Polaris
Honoraria - Bionest Partner; Horizon CME; Research to Practice; Targeted Oncology
Consulting or Advisory Role - Adaptimmune; ADRx; Apexigen; Ayala Pharmaceuticals; Bayer; Cytokinetics; Daiihi Sankyo; Deciphera; EMD Serono; Epizyme; GlaxoSmithKline; Immune Design; Intellisphere; Lilly; Novartis; Pfizer
Speakers' Bureau - Adaptimmune; GlaxoSmithKline; Lilly; Novartis
Research Funding - GlaxoSmithKline; Merck; Pfizer; TRACON Pharma
Patents, Royalties, Other Intellectual Property - Accuronix Therapeutics- Licensing agreement. Sigma-2 Receptor Ligands and Therapeutic uses therefor (006766), • Modular Platform for Targeted Therapeutic Delivery (006755), • Sigma-2 Receptor Ligand Drug Conjugates as Antitumor Compounds, Methods of synth; Patent on ALEXT3102; Patent on the use of ME1 as a biomarker
Expert Testimony - Health Advances
Travel, Accommodations, Expenses - Adaptimmune; Advenchen Laboratories; GlaxoSmithKline; Lilly
 
Matthew Ingham
Consulting or Advisory Role - Apexigen; Caris Life Sciences; Daiichi Sankyo; Epizyme; Xencor
Research Funding - Apexigen (Inst); APICES; Mirati Therapeutics (Inst); PTC Therapeutics (Inst)
Travel, Accommodations, Expenses - Genentech
 
Steven Attia
Research Funding - AB Science (Inst); Adaptimmune (Inst); Advenchen Laboratories (Inst); Bavarian Nordic (Inst); Bayer (Inst); Blueprint Medicines (Inst); BTG (Inst); CBA Pharma (Inst); Deciphera (Inst); Desmoid Tumor Research Foundation; Epizyme (Inst); FORMA Therapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Gradalis (Inst); Immune Design (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Philogen (Inst); PTC Therapeutics (Inst); SpringWorks Therapeutics (Inst); Takeda (Inst); TRACON Pharma (Inst); TRACON Pharma (Inst)
 
Christian Frederick Meyer
Consulting or Advisory Role - Deciphera; Intellisphere
Speakers' Bureau - Novartis
Other Relationship - UpToDate
 
John Baird
Employment - PTC Therapeutics
Stock and Other Ownership Interests - PTC Therapeutics
Patents, Royalties, Other Intellectual Property - PTC Therapeutics
 
Dhiren D'Silva
Employment - PTC Therapeutics
Stock and Other Ownership Interests - PTC Therapeutics
 
Kylie O'Keefe
Employment - PTC Therapeutics
Stock and Other Ownership Interests - PTC Therapeutics
 
Pius Maliakal
Employment - PTC Therapeutics
Stock and Other Ownership Interests - PTC Therapeutics
 
Mona M. Wahba
Employment - PTC Therapeutics
Stock and Other Ownership Interests - AZS; Johnson & Johnson/Janssen; Pfizer
 
Marla Weetall
Employment - PTC Therapeutics
Stock and Other Ownership Interests - PTC Therapeutics
 
Gary K. Schwartz
Stock and Other Ownership Interests - Bionaut Labs; GenCirq; January Therapeutics
Consulting or Advisory Role - Apexigen; Array BioPharma; Astex Pharmaceuticals; Bionaut Labs; Concarlo; Ellipses Pharma; Epizyme; Gencirq; January Therapeutics; Oncogenuity; OnCusp Therapeutics; PureTech; Sellas Life Sciences; Shanghai Pharma
Research Funding - Adaptimmune (Inst); Astex Pharmaceuticals; Astex Pharmaceuticals (Inst); Calithera Biosciences (Inst); Daiichi Sankyo (Inst); Fortress Biotech (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Oxford BioTherapeutics (Inst); SpringWorks Therapeutics (Inst); TopAlliance BioSciences Inc (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Companion diagnostics for CD4 inhibitors (Inst); patent granted to develop a new technology called PNAs for cancer therapy
Travel, Accommodations, Expenses - Array BioPharma; Epizyme; Epizyme; Epizyme